. Author manuscript; available in PMC: 2016 May 18.

Published in final edited form as: J Invest Dermatol. 2015 Jul 27;135(12):2955–2963. doi: 10.1038/jid.2015.296

Table 4. Psoriasis Severity.

Severity Defined by Therapy	Number (%)^a N = 4,638

Mild (n=3,289; 70.9%)

No therapy	763 (23.2)^b
Topicals only	2,526 (76.8)^b

Moderate to Severe^c (n=1,267; 27.3%)

Phototherapy	324 (25.6)^d
Oral Systemics	664 (52.4)^d
Methotrexate	569 (44.9)^d
Cyclosporine	22 (1.7)^d
Acitretin	90 (7.1)^d
Biologics	471 (37.2)^d
Adalimumab	161 (12.7)^d
Etanercept	209 (44.4)^d
Infliximab	107 (16.5)^d
Ustekinumab	37 (2.9)^d

Unknown (n=82; 1.8%)

Percentages do not equal 100 because patients may have received more than one therapy.

Percentages are calculated amongst those with mild psoriasis.

Alefacept was included as a biologic therapy to identify moderate to severe psoriasis but not reported separately per CMS data use agreement due to cell size of 10 or less.

Percentages are calculated amongst those with moderate to severe psoriasis.